EUVIMEDEUVIMED entdecken
Crossref

Delta‐like 1 homolog ( DLK1 ) regulates cancer stemness and chemoresistance of ovarian cancer by CD44 / CD133 upregulation

Chao-Cheng Huang, Jian-Ching Wu, Pei-Chin Chen, Shih-Hsuan Cheng, Mei-Lang Kung, Meng-Hsun Wu, Chen-Hsuan Wu, Wen-Yuan Li, Chien-Shan Wu, Ming-Hong Tai iD

The Journal of Pathology · 2026

DOI: 10.1002/path.70015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2026. Verfasst von Chao-Cheng Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biobank and Tissue Bank, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplastic Stem Cells, Ovarian Neoplasms, AC133 Antigen. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Ministry of Education in Taiwan, Higher-Education-Sprout-Project, Kaohsiung Chang Gung Memorial Hospital, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is a heterogeneous gynecologic malignancy, with most cases diagnosed at an advanced stage. Despite the availability of effective treatments such as surgery and platinum/taxane‐based chemotherapy, advanced ovarian cancer frequently recurs, highlighting the need to investigate mechanisms of chemotherapy resistance. Delta‐like non‐canonical Notch ligand 1 (DLK1), a transmembrane protein of the EGF‐like family, is aberrantly expressed in several cancers. Our previous study demonstrated that DLK1 promotes oncogenic behaviors and epithelial–mesenchymal transition in ovarian high‐grade serous carcinoma. In this study, we observed a positive correlation between DLK1 and stemness markers CD44 and CD133 in human epithelial ovarian cancer using tissue microarray analysis. Overexpression of DLK1 by an adenovirus vector accelerated sphere‐forming capability and upregulated CD44, CD133, and ABCG2 expression in human ovarian cancer cell lines. Conversely, DLK1 silencing by siRNA abolished the stimulatory effects on the stem cell‐like properties and reduced CD44 and CD133 expression in ovarian cancer cells. Furthermore, DLK overexpression by an adenovirus vector enhanced colony formation and suppressed the cisplatin‐ and taxol‐induced death in human ovarian cancer cells. Conversely, DLK1 siRNA reversed cell death and colony formation induced by these chemotherapeutic agents. Finally, we demonstrated that DLK1 regulates CD44, CD133, and ABCG2 expression through the Notch1/AKT/STAT3 signaling pathway, involving the phosphorylation and translocation of STAT3. Collectively, these results suggest that targeting DLK1 may represent a potential therapeutic strategy to improve outcomes in recurrent ovarian cancer following chemotherapy. © 2026 The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmNeoplastic Stem CellsOvarian NeoplasmsAC133 AntigenCalcium-Binding ProteinsHyaluronan ReceptorsCarcinoma, Ovarian EpithelialMembrane ProteinsHumansFemaleUp-RegulationSignal TransductionCell Line, TumorGene Expression Regulation, NeoplasticAntineoplastic AgentsCisplatinSTAT3 Transcription FactorPaclitaxel

Stichwörter der Autor:innen

CD133CD44Notch1STAT3delta‐like 1 homolog (DLK1)drug resistanceovarian cancerstemness

Substanzen

AC133 AntigenPROM1 protein, humanDLK1 protein, humanCalcium-Binding ProteinsHyaluronan ReceptorsCD44 protein, humanAntineoplastic AgentsCisplatinSTAT3 Transcription FactorMembrane Proteins

Autor:innen und Institutionen

  • Biobank and Tissue Bank, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
  • Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Tao-Yuan, Taiwan.

ORCID-Profile: Ming-Hong Tai

Förderung

  • Ministry of Education in Taiwan, Higher-Education-Sprout-Project
  • Kaohsiung Chang Gung Memorial Hospital
  • Ministry of Science and Technology, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital Biobank and Tissue Bank Core Lab
  • National Science and Technology Council

Zitieren

APA

Huang, C. C., Wu, J. C., Chen, P. C., Cheng, S. H., Kung, M. L., Wu, M. H., Wu, C. H., Li, W. Y., Wu, C. S., & Tai, M. H. (2026). Delta‐like 1 homolog ( DLK1 ) regulates cancer stemness and chemoresistance of ovarian cancer by CD44 / CD133 upregulation. The Journal of Pathology. https://doi.org/10.1002/path.70015

Vancouver

Huang CC, Wu JC, Chen PC, Cheng SH, Kung ML, Wu MH, et al. Delta‐like 1 homolog ( DLK1 ) regulates cancer stemness and chemoresistance of ovarian cancer by CD44 / CD133 upregulation. The Journal of Pathology. 2026. doi:10.1002/path.70015

BibTeX
@article{Huang2026,
  author = {Huang, Chao-Cheng and Wu, Jian-Ching and Chen, Pei-Chin and Cheng, Shih-Hsuan and Kung, Mei-Lang and Wu, Meng-Hsun and Wu, Chen-Hsuan and Li, Wen-Yuan and Wu, Chien-Shan and Tai, Ming-Hong},
  title = {Delta‐like 1 homolog ( DLK1 ) regulates cancer stemness and chemoresistance of ovarian cancer by CD44 / CD133 upregulation},
  journal = {The Journal of Pathology},
  year = {2026},
  doi = {10.1002/path.70015}
}
Kostenlos starten →